Attendee search 

Almac provides a comprehensive range of integrated services from research through to commercialisation.  Almac is a financially stable, privately owned organisation with over 3,300 employees located within the US and UK. Over 95% of work is repeat business, testament itself to the quality, innovation, efficiency and the high level of customer satisfaction provided.   

Services Offered
Almac’s integrated solutions extend from research to commercialisation and include:

Biomarker Discovery & Development:
·         Companion Diagnostic Development
·         Genomic Services
·         Bioinformatics Consultancy
·         Proprietary Discovery Arrays 

API Services & Chemical Development:
·         API Development & Manufacture
·         Peptide & Protein Technology
·         Accelerated First in Man Solution
·         Solid State Services
·         Isotope Chemistry
·         Biocatalysis
     
Pharmaceutical Development: 
·         Preformulation & Early Stage Development
·         Scale Up and Late Stage Development
·         Clinical Trial Manufacture
·         Contained Development & Manufacture

Analytical Services:
·         Physical & Chemical Characterisation
·         Method Development & Validation
·         API & Drug Product Testing
·         Stability Testing

Clinical Trial Supply:
·         Comparator Blinding
·         Packaging & Labelling
·         QP Release
·         Global Distribution & Supply Chain Management

Clinical Technologies:
·         IVR / Web
·         ePRO
·         Statistical Services

Commercial Services
·         Manufacturing & Packaging
·         Product Launch & Distribution

Come and see us at booth #64

Oxford BioMedica (LSE:OXB) is a leading gene therapy and immunotherapy company with a platform of exclusive and pioneering technologies to design, develop and manufacture unique gene-based medicines. The Company’s technology platforms include a highly efficient LentiVector® gene delivery system; a single administration to provide long-lasting therapy with specific advantages for targeting CNS and ocular diseases, and a unique tumour antigen (5T4) which is an ideal target for anti-cancer therapy.

The Company’s pipeline addresses diseases for which there is currently no treatment or that are inadequately treated today, including ocular diseases, neurodegenerative disorders and cancer, and its product candidates have the potential to transform treatment landscapes.  Oxford BioMedica’s capabilities cover the entire product lifecycle, from research to development to GMP manufacturing, with collaborative partners such as Sanofi, Pfizer, Novartis and some of the most prestigious clinical centres worldwide.  The Company recently secured significant funding via UK Government competitive awards such as the TSB regenerative medicine/cell therapy grant and AMSCI to build a centre of excellence for specialist manufacture of gene-based therapies.

Through in-house development programmes and industry collaborations, Oxford BioMedica’s goal is to improve the lives of patients with debilitating and life-threatening diseases.  Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

Domainex is a drug discovery company with a reputation for speed and innovation built on an exceptional track record of drug candidate delivery. It has a world class discovery team with an unrivalled track record and three client drug candidates already in clinic.

Domainex reduces industry average drug discovery timelines by as much as 30% through the application of novel proprietary technologies and a highly focussed and integrated approach to medicinal chemistry and computational chemistry. These technologies and Domainex’s approach also enable it to successfully tackle a greater range of drug target classes, such as kinases, proteases, ion channels, proteins involved in epigenetics and protein-protein interactions.

 Domainex has applied its unique technologies and focussed discovery approach to enable it to develop its own pipeline of oncology drugs, including inhibitors of the kinases IKKε/TBK1 for both oncology and inflammation and a number of epigenetics related lysine methyltransferases, including G9a